Amundi Pioneer Asset Management Inc. lessened its stake in shares of Boston Scientific Co. (NYSE:BSX) by 54.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 854,578 shares of the medical equipment provider’s stock after selling 1,010,415 shares during the quarter. Amundi Pioneer Asset Management Inc. owned about 0.06% of Boston Scientific worth $21,186,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in the business. AXA grew its holdings in Boston Scientific by 1.4% during the 4th quarter. AXA now owns 1,249,787 shares of the medical equipment provider’s stock valued at $30,982,000 after buying an additional 17,475 shares during the last quarter. Delpha Capital Management LLC acquired a new stake in shares of Boston Scientific during the fourth quarter worth $135,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Boston Scientific during the fourth quarter worth $1,171,000. Geode Capital Management LLC boosted its holdings in shares of Boston Scientific by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 13,040,987 shares of the medical equipment provider’s stock worth $322,533,000 after purchasing an additional 373,607 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC acquired a new stake in shares of Boston Scientific during the fourth quarter worth $207,000. Hedge funds and other institutional investors own 91.85% of the company’s stock.
Boston Scientific Co. (NYSE:BSX) opened at $28.54 on Tuesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.68 and a quick ratio of 0.49. The firm has a market capitalization of $39,240.00, a price-to-earnings ratio of 40.77, a P/E/G ratio of 2.06 and a beta of 0.82. Boston Scientific Co. has a 52-week low of $24.02 and a 52-week high of $29.93.
In other Boston Scientific news, SVP John Bradley Sorenson sold 1,950 shares of the firm’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $27.43, for a total value of $53,488.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael P. Phalen sold 15,835 shares of the firm’s stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $25.25, for a total value of $399,833.75. The disclosure for this sale can be found here. Insiders sold a total of 174,276 shares of company stock worth $4,592,464 over the last ninety days. Corporate insiders own 0.74% of the company’s stock.
BSX has been the topic of several analyst reports. Zacks Investment Research cut Boston Scientific from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. TheStreet cut Boston Scientific from a “b” rating to a “c+” rating in a report on Thursday, December 7th. BMO Capital Markets restated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a report on Tuesday, December 12th. Canaccord Genuity decreased their price objective on Boston Scientific from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, November 29th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Boston Scientific in a report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $31.06.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.